Alterations in Vesicular Dopamine Uptake Contribute to Tolerance to the Neurotoxic Effects of Methamphetamine

Journal of Pharmacology and Experimental Therapeutics

Volumn 309, Issue 2, 2004, Pages 578-586

  Johnson Davis, Kamisha L ^a   Truong, Jannine G ^a   Fleckenstein, Annette E ^a   Wilkins, Diana G ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; DOPAMINE; DOPAMINE TRANSPORTER; METHAMPHETAMINE; MONOAMINE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; VESICULAR TRANSPORT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINE UPTAKE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG TOLERANCE; HYPERTHERMIA; LONG TERM CARE; MALE; NERVE ENDING; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; DOPAMINE; DRUG TOLERANCE; MALE; METHAMPHETAMINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 2142650653     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.062695     Document Type: Article

References (44)

1. Albers DS and Sonsalla PK (1995) Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J Pharmacol Exp Ther 275:1104-1114.
2. Ali SF, Newport GD, and Slikker W Jr (1996) Methamphetamine-induced dopaminergic toxicity in mice: role of environmental temperature and pharmacological agents. Ann N Y Acad Sci 801:187-198.
3. Bahler M and Greengard P (1987) Synapsin I bundles F-actin in a phosphorylation-dependent manner. Nature 326:704-707.
4. Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W Jr, and Holson RR (1994) Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmcol Exp Ther 268:1571-1580.
5. Bowyer JF, Tank AW, Newport GD, Slikker W Jr, and Holson RR (1992) The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum. J Pharmacol Exp Ther 260:817-824.
6. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
7. Brown JM, Hanson GR, and Fleckenstein AE (2000) Methamphetamine rapidly decreases vesicular dopamine uptake. J Neurochem 74:2221-2223.
8. Brown JM, Riddle EL, Sandoval V, Weston RK, Hanson JE, Crosby MJ, Ugarte YV, Gibb JW, Hanson GR, and Fleckenstein AE (2002) A single methamphetamine administration rapidly decreases vesicular dopamine uptake. J Pharmacol Exp Ther 302:497-501.
9. Chapin DS, Lookingland KJ, and Moore KE (1986) Effects of LC mobile phase composition on retention times for biogenic amines and their precursors and metabolites. Curr Sep 7:68-71.
10. Cubells JF, Rayport S, Rajindron G, and Sulzer D (1994) Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular stress. J Neurosci 14:2260-2771.
11. De Camilli P, Cameron R, and Greengard P (1983a) Synapsin I (protein I), a nerve terminal-specific phosphoprotein: I. Its general distribution in synapses of the central and peripheral nervous system demonstrated by immunofluorescence in frozen and plastic sections. J Cell Biol 96:1337-1354.
12. De Camilli P, Harris SM Jr, Huttner WB, and Greengard P (1983b) Synapsin I (Protein I), a nerve terminal-specific phosphoprotein: II. Its specific association with synaptic vesicles demonstrated by immunocytochemistry in agarose-embedded synaptosomes. J Cell Biol 96:1355-1373.
13. Drukarch B and Stoof JC (1990) D-2 dopamine autoreceptor selective drugs: do they really exist? Life Sci 47:361-376.
14. Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, and Hanson GR (1997) Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 282:834-838.
15. Fumagalli F, Gainetdinov RR, Valenzano KJ, and Caron MG (1998) Role of dopamine transporter in methamphetamine-induced neurotoxicity: evidence from mice lacking the transporter. J Neurosci 18:4861-4869.
16. Fumagalli F, Gainetdinov RR, Wang YM, Valenzano KJ, Miller GW, and Caron MG (1999) Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knock-out mice. J Neurosci 19:2424-2431.
17. Gibb JW, Hanson GR, and Johnson M (1994) Neurochemical mechanisms of toxicity, in Amphetamine and Its Analogs (Cho AK and Segal DS eds) pp 269-295, Academic Press, San Diego, CA
18. Graham DG, Tiffany SM, Bell WR Jr, and Gutknecht WF (1978) Autooxidation versus covalent binding of quinines as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 14:644-653.
19. Gygi MP, Gygi SP, Johnson M, Wilkins DG, Gibb JW, and Hanson GR (1996) Mechanisms for tolerance to methamphetamine effects. Neuropharmacololgy 35: 751-757.
20. Hastings TG (1995) Enzymatic oxidation of dopamine: role of prostaglandin H synthase. J Neurochem 64:919-924.
21. Hogan KA, Staal RGW, and Sonsalla PK (2000) Analysis of VMAT2 binding after methamphetamine or MPTP treatment: disparity between homogenates and vesicle preparations. J Neurochem 74:2217-2220.
22. Hotchkiss AJ and Gibb JW (1980) Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther 214:257-262.
23. Huttner WB, Schiebler W, Greengard P, and De Camilli P (1983) Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation. J Cell Biol 96:1374-1388.
24. Johnson-Davis KL, Fleckenstein AE, and Wilkins DG (2003) The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity. Eur J Pharmacol 482:151-154.
25. Kogan FJ, Nichols WK, and Gibb JW (1976) Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur J Pharmacol 36:363-371.
26. Liu Y and Edwards RH (1997) The role of vesicular transport proteins in synaptic transmission and neural degeneration. Annu Res Neurosci 20:125-156.
27. Llinas R, McGuinness TL, Leonard CS, Sugimori M, and Greengard P (1985) Intraterminal injection of synapsin I or calcium/calmodulin-dependent protein kinase II alters neurotransmitter release at the squid giant synapse. Proc Natl Acad Sci USA 82:3035-3039.
28. Lorez H (1981) Fluorescence histochemistry indicates damage of striatal dopamine nerve terminals in rats after multiple doses of methamphetamine. Life Sci 28: 911-916.
29. Lowry OH, Rosebrough N, Farr A, and Randall R (1951) Protein measurements with folin phenol reagent. J Biol Chem 193:265-275.
30. Marek GJ, Vosmer G, and Seiden LS (1990) Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons. Brain Res 513:274-279.
31. Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang SC, and Phelps ME (1997) Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res 766:113-120.
32. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, and Moore RY (1982) Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 235:93-103.
33. Riddle EL, Topham MK, Haycock JW, Hanson GR, and Fleckenstein AE (2002) Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaine. Eur J Pharmacol 449:71-74.
34. Sandoval V, Riddle EL, Hanson GR, and Fleckenstein AE (2003) Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J Pharmacol Exp Ther 304:1181-1187.
35. Schmidt CJ, Gehlert DR, Peat MA, Sonsalla PK, Hanson GR, Wamsley JK, and Gibb JW (1985) Studies on the mechanism of tolerance to methamphetamine. Brain Res 343:305-313.
36. Seiden LS, Fischman MW, and Schuster CR (1976) Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1:215-219.
37. Stephans S and Yamamoto B (1996) Methamphetamine pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity. Neuroscience 72: 593-600.
38. Stoof JC and Kebabian JW (1981) Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum. Nature 294:366-368.
39. 3H]dopamine uptake. J Pharmacol Exp Ther 280:1432-1444.
40. Ugarte YV, Rau KS, Riddle EL, Hanson GR, and Fleckenstein AE (2003) Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptors. Eur J Pharmacol 472:165-171.
41. Vallar L and Meldolesi J (1989) Mechanisms of signal transduction at the dopamine D2 receptor. Trends Pharmacol Sci 10:74-77.
42. Wagner GC, Ricaute G, Seiden LS, Schuster CR, Miller RJ, and Westley J (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 181:151-160.
43. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, Schmunk GA, Shannak K, Haycock JW, and Kish SJ (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703.
44. Woolverton WL, Ricaurte GA, Forno LS, and Seiden LS (1989) Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res 486:73-78.